Session will explores the current status and future outlook around, Reimbursement, and Management Strategies for Orphan Drugs, Rare and Ultra Rare Diseases, including cell and gene therapy (CGT) landscape, highlighting key market access challenges, and considerations for optimizing patient access.
Негізгі бет Market Insight to Rare Diseases and Gene Cell Therapy
Пікірлер